1. Home
  2. MESO

as 10-03-2025 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Founded: 2004 Country:
Australia
Australia
Employees: N/A City: N/A
Market Cap: 1.3B IPO Year: N/A
Target Price: $24.00 AVG Volume (30 days): 283.4K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.08 EPS Growth: N/A
52 Week Low/High: $7.09 - $22.00 Next Earning Date: 08-28-2025
Revenue: $17,198,000 Revenue Growth: 191.39%
Revenue Growth (this year): 288.5% Revenue Growth (next year): 173.73%

MESO Daily Stock ML Predictions

Share on Social Networks: